zolpidem

(redirected from Ambien CR)
Also found in: Medical, Wikipedia.

zol·pi·dem

 (zōl′pə-dĕm′)
n.
A non-benzodiazepine sleep-inducing drug, C19H21N3O, used in its tartrate form to treat insomnia.

[(a)zol(e) + p(yrim)id(ine) + alteration of am(ide).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

zolpidem

(ˈzɒlpɪˌdɛm)
n
a drug used to treat insomnia
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

zolpidem

n zolpidem m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
These behaviors appear to be more common with Lunesta, Sonata, Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist than other prescription medicines used for sleep.
In 2005, 6,000 emergency-room cases nationwide involved Ambien and other medications containing the hypnotic drug zolpidem--such as Ambien CR, Edluar and Zolpimist.
An extended-release form of zolpidem (Ambien CR) is also available.
A Zolpidem (generic), sold also under brand names Ambien, Ambien CR (extended release), Edluar (sublingual, which means under the tongue), and Zolpimist (oral spray), has been found to cause next-morning impairment for activities that require patients to be alert, including driving.
Food and Drug Administration has announced new, lower dosing requirements for certain sleep drugs that contain zolpidem, including Ambien, Ambien CR, Edluar, and ZolpiMist.
Food and Drug Administration announced new, lower dosing requirements for certain sleep drugs that contain zolpidem, including Ambien, Ambien CR, Edluar, and ZolpilAist.
As the first company to file an ANDA that contained a paragraph IV certification for Ambien CR 6.25mg, Actavis has been awarded 180-day exclusivity to market this product.
Sanofi-Aventis's dominance in the insomnia market is under threat due to patent challenges to Ambien CR and Datamonitor expects generic versions of this market leading brand to enter the US over the forecast period.
from Tecumseh, Michigan: Studies of Ambien (zolpidem tartrate) and Ambien CR (controlled-release) suggest no long-term effect on memory or brain performance in people taking the prescription sleep aid.
In a lawsuit filed in Newark, New Jersey federal court, Sanofi claimed Barr's product would infringe on its patent for the active ingredient in its time-release version of the sleeping pill marketed as Ambien CR. "The commercial manufacture, use, offer for sale and/or importation" of the generic pill will infringe on Sanofi's patent, attorney William O'Shaughnessy said in the company's complaint.